Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

German Merck Aims To Lift Its UK R&D Efforts, Despite Brexit Uncertainty

Executive Summary

Germany's Merck Group plans to bolster its biopharma R&D activities in Britain - despite Brexit - on grounds the UK is too key and dynamic a player in the life sciences sphere not to - and because the conglomerate needs to be there to help ensure its evolution into a top oncology and immuno-oncology innovator.

You may also be interested in...



CHMP OK Puts Merck KGaA's Cladribine Pill On EU Home Stretch After Long Trek

Merck of Germany's oral multiple sclerosis medicine cladribine looks set to finally get EU approval. But the long, slow race it has had to endure - and time lost getting there - may curb sales.

2Q Pharma Results Preview: Pfizer, Shire, Merck KGaA, Teva, Novo Nordisk And Allergan

Pfizer, Merck KGaA, Novo Nordisk, Shire, Allergan and Teva are among those pharmaceutical majors still to report their 2Q results. Scrip considers what’s in store.

German Merck Identifies Pipeline Stars, Plots Course Through A Dynamic Cancer Space

As questions remain over Merck KGAA's ability to retain its top line following the patent loss for its key products Rebif and Erbitux, the German company has highlighted some of its higher priority R&D programs in its "very interesting" pipeline, as well as its strategy to make the most of the assets.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel